Stryker boosts IGA (international government affairs) with high-profile appointment
This article was originally published in Clinica
Executive Summary
Orthopaedics industry market leader Stryker has appointed international medical device industry and government affairs specialist Ed Rozynski to head its newly-created international government affairs (IGA) function. The appointment of Mr Rozynski as vice-president of international government affairs appears to be part of a concerted effort by the Kalamazoo, Michigan company to raise its profile on public policy and reimbursement issues. Stryker International president Luciano Cattani said: "Ed brings a wealth of experience and expertise and visibility to this role. His worldwide perspective and advice is sought out by foreign healthcare leaders." Mr Rozynski was most recently vice-president of international government affairs at St Jude Medical (focusing on developing strategy and international market access), prior to which he served as an international consultant to the industry, helping to secure favourable reimbursement and policy outcomes in Japan, Europe and the Americas. His healthcare industry responsibilities have also included 12 years with AdvaMed. At Stryker, he will also act as adviser to CEO Steve MacMillan, who has just assumed the chairmanship of AdvaMed's international committee.
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.